Literature DB >> 1712030

Liposomes as carriers of antigens and adjuvants.

C R Alving1.   

Abstract

Liposomes have been widely used as carriers of protein or peptide antigens. Antigenic materials can be attached to the outer surface, encapsulated within the internal aqueous spaces, or reconstituted within the lipid bilayers of the liposomes. The natural tendency of liposomes to interact with macrophages has served as the primary rationale for utilizing liposomes as carriers of antigens. Liposomes also serve as carriers of a variety of adjuvants and mediators, including lipid A, muramyl dipeptide and its derivatives, interleukin-1, and interleukin-2. Research utilizing in vitro cell culture models has demonstrated that liposomes containing both appropriate antigens and major histocompatibility gene complex molecules can induce antigen-specific genetically restricted cytotoxic T lymphocytes. Liposomes induce immune reactions through classical interactions with antigen presenting cells. However, modelling experiments have also demonstrated that liposomes can even substitute for antigen presenting cells, and cell-free genetically restricted and nonrestricted presentation of antigens by liposomes to helper T lymphocytes has been demonstrated. Liposomes are successful for inducing potent immunity in vivo and they are now being employed in numerous immunization procedures and as vehicles for candidate vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712030     DOI: 10.1016/0022-1759(91)90120-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  46 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 3.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

4.  Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages.

Authors:  J N Verma; M Rao; S Amselem; U Krzych; C R Alving; S J Green; N M Wassef
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

5.  Induction of primary antigen-specific immune reponses in SCID-hu-PBL by coupled T-B epitopes.

Authors:  P Ifversen; C Mårtensson; L Danielsson; C Ingvar; R Carlsson; C A Borrebaeck
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

6.  Liposome-entrapped T-cell peptide provides help for a co-entrapped B-cell peptide to overcome genetic restriction in mice and induce immunological memory.

Authors:  G Gregoriadis; Z Wang; Y Barenholz; M J Francis
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

7.  Modification of alpha 2-macroglobulin into a macrophage-activating factor through the action of liposome-stimulated B-cell membranous glycosidases.

Authors:  M Murai; Y Aramaki; S Tsuchiya
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

8.  Identification of the serum factor required for liposome-primed activation of mouse peritoneal macrophages. Modified alpha 2-macroglobulin enhances Fc gamma receptor-mediated phagocytosis of opsonized sheep red blood cells.

Authors:  M Murai; Y Aramaki; S Tsuchiya
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

9.  Role of liposomes in selective proliferation of splenic lymphocytes.

Authors:  S Sehra; L Chugh; S V Gangal
Journal:  Mol Cell Biochem       Date:  1998-06       Impact factor: 3.396

10.  A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.

Authors:  Yun Hu; Hong Zheng; Wei Huang; Chenming Zhang
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.